Jesús S. G.
- Country
- Spain
- Department
- Enfermedades Infecciosas
Research Overview
- A Phase 3 Open-label Clinical Study of Doravirine/Islatravir (DOR/ISL [100 mg/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL (100 mg/0.75 mg) QD in a Phase 3 Clinical Study
- A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)
- Phase 3 Randomized Double‑Blind Study of Doravirine/Islatravir Versus Bictegravir Combination Therapy in Treatment‑Naïve HIV‑1 Infection
Data & Insights
Has run more than one trial at 38 of 60 partner sites.
Specializations
HIV Treatment Research
This investigator specializes in antiretroviral therapy and treatment strategies for patients with HIV-1 infection. Their research focuses on evaluating novel therapeutic combinations and treatment switches in different patient populations.
- Treatment-naive patients
- Treatment-experienced patients
- Treatment switching strategies
Therapeutic Focus
The investigator studies innovative antiretroviral combinations, particularly involving doravirine and islatravir. Their work encompasses comparative assessments with established therapies such as bictegravir/emtricitabine/tenofovir alafenamide.
- Novel drug combinations
- Comparative therapy studies
- Long-term treatment efficacy
Clinical Outcomes
The investigator's research emphasizes measuring viral suppression and treatment safety in HIV-1 patients. Their work includes monitoring antiretroviral activity and evaluating therapeutic tolerability across different treatment regimens.
- Viral load monitoring
- Safety assessment
- Treatment tolerability
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.